171 related articles for article (PubMed ID: 20072155)
21. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
Suresh K; Fraser G; Scheid E; Leber B; Gauldie J; Foley R
Leuk Lymphoma; 2006 Feb; 47(2):297-306. PubMed ID: 16321861
[TBL] [Abstract][Full Text] [Related]
22. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages.
Hus I; Kawiak J; Tabarkiewicz J; Radej S; Hoser G; Bojarska-Junak A; Schmitt M; Giannopoulos K; Dmoszynska A; Rolinski J
Oncol Rep; 2008 Aug; 20(2):443-51. PubMed ID: 18636210
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
Hus I; Roliński J; Tabarkiewicz J; Wojas K; Bojarska-Junak A; Greiner J; Giannopoulos K; Dmoszyńska A; Schmitt M
Leukemia; 2005 Sep; 19(9):1621-7. PubMed ID: 15990861
[TBL] [Abstract][Full Text] [Related]
25. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.
Müller MR; Tsakou G; Grünebach F; Schmidt SM; Brossart P
Blood; 2004 Mar; 103(5):1763-9. PubMed ID: 14615377
[TBL] [Abstract][Full Text] [Related]
26. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
[TBL] [Abstract][Full Text] [Related]
27. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
28. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
29. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
Mikaelsson E; Danesh-Manesh AH; Lüppert A; Jeddi-Tehrani M; Rezvany MR; Sharifian RA; Safaie R; Roohi A; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Blood; 2005 Jun; 105(12):4828-35. PubMed ID: 15741214
[TBL] [Abstract][Full Text] [Related]
30. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
31. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes.
Granziero L; Circosta P; Scielzo C; Frisaldi E; Stella S; Geuna M; Giordano S; Ghia P; Caligaris-Cappio F
Blood; 2003 Mar; 101(5):1962-9. PubMed ID: 12406905
[TBL] [Abstract][Full Text] [Related]
32. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
34. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
35. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
36. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.
Alfarano A; Indraccolo S; Circosta P; Minuzzo S; Vallario A; Zamarchi R; Fregonese A; Calderazzo F; Faldella A; Aragno M; Camaschella C; Amadori A; Caligaris-Cappio F
Blood; 1999 Apr; 93(7):2327-35. PubMed ID: 10090943
[TBL] [Abstract][Full Text] [Related]
37. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
38. B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
Gross E; L'Faqihi-Olive FE; Ysebaert L; Brassac M; Struski S; Kheirallah S; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Nov; 24(11):1885-92. PubMed ID: 20827287
[TBL] [Abstract][Full Text] [Related]
39. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046
[TBL] [Abstract][Full Text] [Related]
40. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
